

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the instant application. The present status of each claim is indicated in parentheses following the claim number. An instruction line precedes each claim that is amended, cancelled, or added by the instant paper.

1-13 CANCELLED

Please **amend** claim 14 as follows:

14. (CURRENTLY AMENDED) An *in vitro* method for producing ~~Langerhans~~ type dendritic ~~dendritic~~ Langerhans cells, said method comprising:
- a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells in a medium containing mammalian platelets; and
  - b. incubating the culture at about 30°C to about 40°C for a period sufficient to enable formation of mature ~~Langerhans~~ type dendritic ~~dendritic~~ Langerhans cells,
- wherein the medium omits an exogenous cytokine.

15. (PREVIOUSLY PRESENTED) The method as claimed in claim 14, wherein the exogenous cytokine is granulocyte macrophage colony stimulating factor or interleukin-4.
16. (PREVIOUSLY PRESENTED) The method as claimed in claim 14 wherein the medium comprises RPMI-1640.
17. (PREVIOUSLY PRESENTED) The method as claimed in claim 14 wherein the cells are cultured for a period of about 2 to about 8 days.
18. (PREVIOUSLY PRESENTED) The method as claimed in claim 14 wherein the medium further comprises fetal calf serum.
19. (PREVIOUSLY PRESENTED) The method as claimed in claim 18, wherein the medium contains at least about 2% fetal calf serum.
20. (PREVIOUSLY PRESENTED) The method as claimed in claim 19, wherein the fetal calf serum is about 10%.

Please **amend** claim 21 as follows:

21. (CURRENTLY AMENDED) The method as claimed in claim 14 wherein human platelets are added to the medium to

develop ~~Langerhans~~ =type=dendritic dendritic Langerhans cells.

Please **amend** claim 22 as follows:

22. (CURRENTLY AMENDED) The method as claimed in claim 14 wherein rat platelets are added to the medium containing mice blood cells to develop ~~Langerhans~~ =type=dendritic dendritic Langerhans cells.

Please **amend** claim 23 as follows:

23. (CURRENTLY AMENDED) A method for producing ~~Langerhans~~ =type=dendritic dendritic Langerhans cells *in vitro* comprising:
- a. preparing peripheral blood monocytes and/or bone marrow cells; and
  - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium lacking an exogenous cytokine such that ~~Langerhans~~ =type=dendritic dendritic Langerhans cells are produced.

Please **amend** claim 24 as follows:

24. (CURRENTLY AMENDED) The method of claim 23 further comprising analyzing the morphology of human ~~Langerhans =type dendritiedendritic~~ Langerhans cells produced.

Please **amend** claim 25 as follows:

25. (CURRENTLY AMENDED) The method of claim 23 further comprising analyzing the ~~Langerhans =type dendritiedendritic~~ Langerhans cells produced by flow cytometry.

Please **amend** claim 26 as follows:

26. (CURRENTLY AMENDED) The method of claim 23 wherein the peripheral blood monocytes, the platelets, and the ~~Langerhans =type dendritiedendritic~~ Langerhans cells produced are human.

Please **amend** claim 27 as follows:

27. (CURRENTLY AMENDED) The method of ~~claim 23~~claim 14 wherein the bone marrow cells are mouse bone marrow cells, the platelets are rat platelets, and the ~~Langerhans =type dendritiedendritic~~ Langerhans cells produced are mouse ~~Langerhans =type dendritiedendritic~~ Langerhans cells.

Please **amend** claim 28 as follows:

28. (CURRENTLY AMENDED) An *in vitro* method for producing ~~Langerhans type dendritiedendritic~~ Langerhans cells, said method comprising:
- a. culturing cells selected from the group consisting of peripheral blood monocytes and bone marrow cells in a medium containing mammalian platelets; and
  - b. incubating the culture at about 30°C to about 40°C for a period sufficient to enable formation of mature ~~Langerhans type dendritiedendritic~~ Langerhans cells.

Please **amend** claim 29 as follows:

29. (CURRENTLY AMENDED) A method for producing  
~~Langerhans type dendritic~~dendritic Langerhans cells in  
vitro comprising:

- a. preparing peripheral blood monocytes and/or bone marrow cells; and
- b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium such that ~~Langerhans type dendritic~~dendritic Langerhans cells are produced.

Please **amend** claim 30 as follows:

30. (CURRENTLY AMENDED) A method for producing  
~~Langerhans type dendritic~~dendritic Langerhans cells in  
vitro comprising:

- a. preparing peripheral blood monocytes and/or bone marrow cells; and
- b. culturing the peripheral blood monocytes or the bone marrow cells with platelets in a culture

medium such that ~~Langerhans-type~~

~~dendritic~~dendritic Langerhans cells are produced,

wherein the peripheral blood monocytes and/or bone marrow cells and the platelets may be independently selected from the group of rat cells and mouse cells.

31. (PREVIOUSLY PRESENTED) The method of claim 30, wherein the culture medium lacks an exogenous cytokine.
32. (WITHDRAWN) A method for producing mature dendritic cells *in vitro* comprising:
- a. preparing peripheral blood monocytes and/or bone marrow cells; and
  - b. culturing the peripheral blood monocytes or the bone marrow cells with platelets of the same species in a culture medium such that mature dendritic cells are produced,
- wherein more than about 50% of the mature dendritic cells have dendritic processes and display reactivity to anti-HLA-DR, anti-CD40, and anti-CD86 monoclonal antibodies and less than about 20% of the mature

dendritic cells display reactivity to anti-CD1a, anti-CD80, and anti-CD83 monoclonal antibodies.

33. (WITHDRAWN) The method of claim 32, wherein the culture medium lacks an exogenous cytokine.
34. (NEW) The method of claim 23 wherein the peripheral blood monocytes are human peripheral blood monocytes, the platelets are human platelets, and the dendritic Langerhans cells produced are human dendritic Langerhans cells.